1. Scrip
  2. >>Therapy Areas

Advanced BioHealing hopes for $200 million in IPO

 
• By Nancy Faigen

Advanced BioHealing, a regenerative medicine company developing and commercialising living cell therapies, has filed an initial public offering with US regulators, hoping to raise $186-213 million before deductions part of which will be spent on a second manufacturing facility and part of which may be used for in-licensing or acquisitions. The issue puts for 13.35 million shares on the table with the company hoping for a share price between $14 and $16 each.

Advanced BioHealing, a regenerative medicine company developing and commercialising living cell therapies, has filed an initial public offering with US regulators, hoping to raise $186-213 million before deductions part of which will be spent on a second manufacturing facility and part of which may be used for in-licensing or acquisitions. The issue puts for 13.35 million shares on the table with the company hoping for a share price between $14 and $16 each.

The company, based in Westport, Connecticut, markets the tissue-engineered substitute Dermagraft, which assists in restoring damaged tissue and is currently...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

More from Therapeutic Category

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 
• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.